[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557822":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":21,"armGroups":17,"interventions":22,"overallOfficials":17,"centralContacts":26,"locations":32,"responsibleParty":49,"collaborators":17,"id":52,"slug":17,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":17,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":17,"studyType":63,"phases":17,"briefSummary":64,"conditions":65,"keywords":17,"overallStatus":35,"whyStopped":17,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Hunan Cancer Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"18F-FAPI-04 PET imaging diagnosis of gastric cancer detection rate","Exploring the feasibility of using targeted fibroblast activation protein (FAP) PET\u002FCT imaging for gastric cancer; Compare the advantages and disadvantages of 18F-FAPI-04 and 18F-FDG in gastric cancer imaging, explore the clinical application value of 18F-FAPI-04 PET\u002FCT in gastric cancer imaging, and construct a molecular imaging diagnostic model for gastric cancer","2 years",[14],{"measure":15,"description":16,"timeFrame":12},"Detection rate of peritoneal metastasis in gastric cancer","Comparison of the diagnostic value of 18F-FAPI-04 PET\u002FCT and PET\u002FMR for peritoneal metastasis of gastric cancer, and construction of a molecular imaging diagnostic model for peritoneal metastasis of gastric cancer",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":20,"maskingInfo":17},"COHORT","PROSPECTIVE","Gastric cancer",[23],{"type":24,"name":25,"description":25,"armGroupLabels":17,"otherNames":17},"DIAGNOSTIC_TEST","The clinical value of 18F-FAPI-04 PET\u002FCT and PET\u002FMR imaging in the diagnosis and staging of gastric cancer",[27],{"name":28,"role":29,"phone":30,"phoneExt":17,"email":31},"Hui Ye","CONTACT","86-13755117105","yuxin75831@163.com",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Hunan Cancer hospital","RECRUITING","Changsha","Hunan","410000","China","CN",{"type":42,"coordinates":43},"Point",[44,45],112.97087,28.19874,{"lat":45,"lon":44},[48],{"name":28,"role":29,"phone":30,"phoneExt":17,"email":31},{"type":50,"investigatorFullName":28,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Professor","100557822",false,"NCT06543108","Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET\u002FCT and PET\u002FMR in Gastric Cancer","Inclusion Criteria:\n\n1. Age over 18 years old;\n2. Diagnosed as a patient with gastric cancer;\n3. Receive FAPI PET\u002FCT and FDG PET\u002FCT imaging within one week;\n4. Perform serum tumor marker testing one week before and after scanning\n\nExclusion Criteria:\n\n1. History of other malignant tumors;\n2. Patients with severe infections, severe underlying diseases such as heart, kidney, and liver;\n3. Patients with contraindications for PET-CT examination, poor physical condition, and inability to tolerate the examination;\n4. Patients with unorganized pathology or incomplete clinical data","ALL","18 Years","90 Years",{"count":61,"type":62},30,"ESTIMATED","OBSERVATIONAL","This project aims to comprehensively analyze the diagnostic efficacy of SUVmax, SUVean, TLG, MTV, etc. in gastric cancer through 18F-FAPI-04 PET\u002FCT imaging combined with serum tumor markers and other methods, and construct a molecular imaging diagnostic model for gastric cancer; Next, analyze the diagnostic efficacy of 18F-FAPI-04 PET\u002FCT and PET\u002FMR multimodal imaging in evaluating SUVmax, PET\u002FCT-PCI, and PET\u002FMR-PCI for gastric cancer peritoneal metastasis, and construct a molecular imaging diagnostic model for gastric cancer peritoneal metastasis; Exploring the clinical value of 18F-FAPI-04 PET\u002FCT and PET\u002FMR imaging in the diagnosis and staging of gastric cancer.",[66],"Gastric Cancer","2024-08-03",{"date":69,"type":70},"2024-08-07","ACTUAL",{"date":72,"type":70},"2024-01-01",{"date":74,"type":62},"2028-12-31",{"name":5,"class":6},1]